OINDP specialist contract developer Kenox Pharmaceuticals announced that it has added a clean room for small scale manufacturing of non-sterile nasal sprays and dry powders for use in pre-clinical development. The company, which is located in Princeton, NJ, USA, said that it is also in the process of adding Phase 1 and 2 clinical scale GMP manufacturing capabilities for non-sterile and sterile inhaled and nasal drug products.
According to Kenox’s web site, the company provides developments services for a wide range of OINDPs, including inhalation solutions and suspensions, MDIs, DPIs, nasal sprays. Kenox is also Boehringer Ingelheim’s preferred CRO for Respimat development partnerships; and at RDD 2024, the two companies got together to present a workshop on SMI development.
Kenox President and CEO Sitaram Velaga commented, “I’m so excited about this expansion which was executed in a timely manner. This would not have been possible without our talented and capable team, rockstar QA, support from our partners/clients, various vendors, and the facility management. This expansion reflects our dedication to support our partners in their mission to develop cutting edge therapeutics for unmet medical needs with meticulous attention to quality, efficiency, project goals, and timelines.”
Read the Kenox Pharmaceuticals press release
